US FDA accepts Bristol-Myers' BLA for Opdivo plus low-dose Yervoy to treat first-line advanced NSCLC in patients with TMB=10 mut/Mb

Bristol-Myers Squibb Company (BMS) announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) plus low-dose Yerv...